cyrilzakka/clinical-trials huggingface dataset:
Superb Microvascular Imaging Ultrasonography of Plantar Fasciitis

A prospective study will be conducted to evaluate the diagnostic performance of SMI, gray scale US, color Doppler US and Power Doppler US.

Plantar fasciitis (PF) is a painful condition of the inferior and medial heel. Symptoms worsens with the first steps in the morning or after prolonged sitting and long periods of standing.

The diagnosis of PF is made according to the typical anamnesis and physical examination, based on the emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician. Heel pain exacerbates by the first steps in the morning or after rest and with prolonged standing. Unless there is an inflammatory disease such as spondyloarthropathy, there is no laboratory finding indicating plantar fasciitis. Imaging methods are very useful for making an accurate diagnosis. Because the main problem is in the soft tissue, plain radiography has limited diagnostic value, but can be helpful in identifying calcaneal stress fractures.

Magnetic resonance imaging (MRI) is very successful in showing the inflammatory process of soft tissue. However, it does not seem possible to use MRI scans routinely because of the cost and time it requires.

PF can be evaluated with ultrasonography with the advantages of being non-invasive, relatively inexpensive, easy to access and apply, and is increasingly used in clinical practice. Color Doppler evaluation is a very valuable part of musculoskeletal sonographic examination and facilitates the clinician's decision as an inflammation marker. Power Doppler US is quite sensitive to tissue or probe movement, especially at low pulsed repetition frequency (PRF). Flash artifacts may be observed. However, Doppler USG has limited sensitivity at low flows and small vessel structures.

Superb microvascular imaging (SMI) (Toshiba Medical Systems, Tokyo, Japan) is a new mode of vascular imaging that provides visualization of activity in microvascular structures or in structures that have low flow rate.

To the best of our knowledge, there are no studies comparing the diagnostic performance of the SMI modality in plantar fasciitis with color Doppler and gray scale US. Therefore, a prospective study will be conducted to evaluate the diagnostic performance of SMI, gray scale US, color Doppler US and Power Doppler US. The null hypothesis that there is no difference between Doppler US and SMI methods in the detection of increased inflammatory activity in plantar fasciitis patients.

Eligibility Criteria:
For the first group:

Inclusion Criteria:

* Patients who diagnosed as Plantar Fasciitis
* Age between 18-45

Exclusion Criteria:

* History of foot trauma or surgery
* Diabetes mellitus
* Pregnancy,
* Rheumatological diseases

For the second group:

Inclusion Criteria:

* asymptomatic foot,
* no previous trauma or surgery on foot,
* no history of systemic inflammatory disorders.

Exclusion Criteria:

* History of foot trauma or surgery
* Diabetes mellitus
* Pregnancy,
* Rheumatological diseases
Power During Functional Tasks in Older Adults

The primary aim of this study is to optimize the methodology to measure lower limb power in older adults, so that clinicians are able to detect functional problems in this population earlier.

Aging is associated with slower movement patterns, a higher fall risk and a restriction in functionality. This will lead to an increase in the number of dependent elderly and a high socio-economic burden. From the age of 40, a systematic loss of muscle mass and muscle force, also known as sarcopenia, will occur. In addition, performing daily tasks requires the production of muscle force at a certain speed. The product of force and speed, power, decreases even earlier and faster than muscle force.

This power is typically measured with specialized equipment, which limits the large-scale applicability. With the help of accelerometry there is the possibility to measure power during more functional tasks and movements, which benefits the applicability, but the reliability, reference values and link with other outcome measurements related to sarcopenia has to be investigated.

Eligibility Criteria:
Inclusion Criteria:

* Age \>20

Exclusion Criteria:

* Unstable cardiovascular diseases
* Fever or acute infection
* Cognitive or physical malfunctioning that hinders the understanding or performance of tests and/or instructions
Study of ONO-8539 in Patients With Overactive Bladder

The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.


Eligibility Criteria:
Inclusion Criteria:

* Patients with medical history of Overactive Bladder symptoms for \> 6 months

Exclusion Criteria:

* Patients who have a history or presence of other significant diseases, which in the opinion of the investigator, might compromise the patient's safety or the evaluation of the study results
Bi-level vs. Single Level ESB in VATS

Video assisted thoracoscopic surgery (VATS) is a minimally invasive surgery to remove lesions from the thoracic cavity. It is associated with moderate pain which can lead to pulmonary complications after surgery. The Enhanced Recovery After Surgery (ERAS) and the European Society of Thoracic Surgeons recommended a multimodal analgesia approach to manage pain after VATS. Erector spinae block (ESB) is a popular analgesic block due to its ease of performance and wide coverage. It has been shown to be effective in randomized control trials. Recently, case reports on bi-level ESB are emerging, suggesting more effective analgesia compared to single level ESB. As there is no available data, the investigators are interested in conducting a randomized pilot study, comparing bi-level to single level ESB to gather baseline data for sample size calculation for a formal randomized trial.


Eligibility Criteria:
Inclusion Criteria:

* adult patients (at least 18 years old)
* elective unilateral wedge resection, segmentectomy, lobectomy or bilobectomy via VATS

Exclusion Criteria:

* history of malignant hyperthermia
* BMI \> 40, chronic pain condition
* Daily opioid consumption of more than 60 mg oral morphine equivalents
* Conversion to thoracotomy
* Insertion of epidural
* postoperative admission to ICU
Ultrasound Guided Erector Spinae Block for Postoperative Analgesia in Thoracotomy Patients

aim of this study is to assess and compare between the efficacy of the new U/S guided erector spinae plane block (ESP) and the conventional methods of systemic analgesics in adult patients scheduled for elective thoracotomy surgery.

Thoracotomy is considered the most painful of surgical procedures and providing effective analgesia is the onus for all anesthetists. Ineffective pain relief impedes deep breathing, coughing, and remobilization culminating in atelectasis and pneumonia.The erector spinae plane (ESP) block is a newly-described technique for treating thoracic pain, and has several advantages that make it an attractive alternative to these more invasive procedures.Ultrasound guided erector spinae (ESP) block is a regional anesthesia technique, recently described by (Forero; et al.) for use in thoracic neuropathic pain. ESP block is reported to lead to analgesic effect on somatic and visceral pain by effecting the ventral rami and rami communicantes that include sympathetic nerve fibers, as LA spreads through the paravertebral space . When performed bilaterally it has been reported to be as effective as thoracic epidural analgesia.ESP block leads to effective postoperative analgesia when performed at T 4-5 level for breast and thoracic surgery. The ESP block , will be performed as follow:The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.

Eligibility Criteria:
Inclusion Criteria:

* patients aged \>18 years
* American Society of Anesthesiologists Physical Status I or IV scheduled for elective thoracotomy

Exclusion Criteria:

* Refusal of the patient to provide written consent
* history of relevant drug allergy
* age less than 18
* obesity BMI \> 40 kg/m2
* infection of the skin at the site of needle puncture area
* coagulopathy
* Pregnant females
In-vitro Effect of Mangosteen Pericarp Extract on Cell Lines

The present study is an effort to investigate the hypothesis that in-vitro vitality and antiapoptotic effect of alcoholic crude extract of mangosteen on Oral cancer( H357) cell lines and Cevical cancer (HeLa) cell lines.

The oral and cervical cells were investigated by MTT (3-4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, DNA fragmentation detection by TUNEL (Terminal deoxynucleotidyl transferase-mediated d-UTP Nick End Labeling) assay and Apototic assay using Annexin V/FITC Kit.

Eligibility Criteria:
Inclusion Criteria:

* Patients with oral squamous cell carcinoma
* Patients with cervical carcinoma

Exclusion Criteria:

• Patients with leukaemia
Exercise Intervention and Running Biomechanics in Older Adults

The goal of this study is to understand the effects of muscle strengthening and stretching exercise intervention on isometric muscle strength, joint flexibility and running biomechanical patterns in older recreational runners. To do so, the subjects will be assessed before and after they engage in a 8-week exercise intervention program.


Eligibility Criteria:
Inclusion Criteria:

* no injuries of the lower extremity within 3 months prior to participation
* running recreationally 2-3 times/week
* familiar and comfortable with treadmill running
* in good health upon entry into the study
* no use of orthotics in the shoe

Exclusion Criteria:

* lower extremity injury within the last 3 months
* surgery to the lower extremity within the last 8 months
* head injury/vestibular disorder within the last 6 months
* inability to speak or read English.
Diagnostic Value of Recto-perineal Ultrasound in Perianal Fistula

Perianal fistula is a common anal problem. It needs only surgery. MRI is the best preoperative diagnostic tool, but it is demanding as it is expensive, time consuming and needs an experienced radiologist. So, we tried to find an alternative diagnostic tool which is cheaper, time saving and accurate and comparing its preoperative reports with intraoperative findings.

study was held in surgery department in Zagazig University Hospitals from September 2023 to March 2024. It included 93 patients with perianal fistula who were diagnosed clinically and radiological by trans recto-perineal ultrasound and comparing pre-operative ultrasound findings with intra-operative surgical findings.


Eligibility Criteria:
Inclusion Criteria:

* Perianal abscess and\\or fistula
* Patients who accidently discovered during transvaginal ultrasound.
* Age group between above 18 years old

Exclusion Criteria:

* Informed consent refusal.
* Proved anal malignancy.
* Patients less than 18 years old
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF). The duration is 3 months of treatment and a 30 day follow-up visit.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female, 18 to 80 years old.
2. Able to provide written informed consent.
3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)
4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke (CHADS2) index score of at least 2

Exclusion Criteria:

1. Subjects with mitral valve disease or previous valvular heart surgery
2. Known contraindication to any anticoagulant including vitamin K antagonists such as warfarin
3. Known or suspected hereditary or acquired bleeding or coagulation disorder
Physiologic Signals and Signatures With the Accuryn™ Monitoring System in Intensive Care Patients

The purpose of the study is to collect physiologic data streams with the Accuryn Monitoring System and validate the accuracy of these measurements against existing gold standards, and to track and analyze changes in these physiologic data streams to identify clinical signatures that may enable earlier diagnosis and intervention of critical conditions.


Eligibility Criteria:
Inclusion Criteria:

* Admission to the hospital with trauma (including burn)
* Anticipated ICU stay of at least 72 hours
* Anticipated transfusion of ≥1 unit blood products (pRBC's, platelets, and/or plasma) within the first 24 hours of hospitalization, and/or a current diagnosis of sepsis/septic shock, and/or ICU admission primarily for burn
* Anticipated requirement for a urinary bladder catheter for ≥ 72 hours

Exclusion Criteria:

* Inability to receive a 16F urinary bladder catheter
* Significant bladder or urethral injury
* In the opinion of the investigator the patient is unsuitable for the study for any other legitimate reason including incarceration, pre-existing medical or psychiatric condition, or interfering medications
* Known previous or concurrent enrollment in a clinical trial that, in the opinion of the investigator, might interfere with the objectives of this clinical trial
* Pregnancy known at the time of presentation
Assessing Cognitive Performance Among Adults With Attention Disorders Working on Treadmill

Randomized clinical trial in which individuals who have been diagnosed with ADHD and are regularly treated with Methylphenidate will be test for cognitive performance and will be randomly examined in the following four conditions:

* While taking Methylphenidate and sitting at a desk
* While taking Methylphenidate and walking on a treadmill workstation
* Without taking Methylphenidate while sitting at a desk
* Without taking Methylphenidate while walking on a treadmill workstation The investigators will compare the cognitive achievements outcomes and evaluate the efficiency of studying in each of these four conditions.

The rationale of this clinical trial is to identify the intervention that best contributes to better cognition results of adults with ADHD's: physical activity, drug or a combination of the two? The study will enable to determine which factor will improve cognitive results. The findings of this trial will help determine the best treatment method that can be offer to adults with ADHD.

Eligibility Criteria:
Inclusion Criteria:

\* Insured by Maccabi Health Services

* Diagnosed with ADHD by Neurologist/Psychiatrist/Developmental Doctor
* Take Methylphenidate as part of the treatment for ADHD AND have agreed to not take the drug if asked to
* Understand the language and simple instruction
* Willing to participate in the study and sign the agreement form

Exclusion Criteria:

* Suffer from heart disease or chronic respiratory illness
* Women who are pregnant
Controlling Hyperadrenergic Activity in Neurologic Injury

Traumatic brain injury (TBI) is frequently associated with a hyperadrenergic state accompanied by elevated levels of plasma catecholamines. In its more severe presentation, the hyperadrenergic state presents as dysautonomia, which is characterized by paroxysmal alteration in vital signs, including tachycardia. The investigators hypothesize that intravenous (IV) esmolol is as effective at controlling heart rate in hyperadrenergic states as oral propranolol, which is the standard of care. Our primary endpoint is efficacy of IV esmolol vs a PRN regimen of intermittent B-blockade in controlling heart rate below a pre-specified level (\< 100 bpm) after Traumatic Brain Injury (TBI) or hemorrhagic neurologic injury. Heart rates will be recorded continuously as well as hourly.


Eligibility Criteria:
Inclusion Criteria:

* TBI (Moderate/Severe TBI (GCS 12 or Head AIS\>1) or hemorrhagic neurologic injury
* Hyperadrenergic Activity: At least one paroxysmal episode (lasting at least 15 minutes) of Heart Rate 110 beats per minute during two or more consecutive days plus at least two more of the following that may not be better explained by another disease process (ex: sepsis):

Temperature of 38.5C Respiratory Rate 20 breaths per minute Agitation Diaphoresis Dystonia Stimulus responsive ("triggering of paroxysm")

- Informed Consent obtained

Exclusion Criteria:

* Patients that do not meet criteria for dysautonomia (as stated above)
* Age \<18 years
* Pregnancy
* Hypotension - requiring pressor therapy to maintain baseline adequate CPP or mean arterial pressure
* Cardiac arrhythmia - sinus bradycardia (HR \<60), 2nd or 3rd degree AV block
* Hemodynamic contraindications to intravenous beta-blockade such as a documented history of congestive heart failure (CHF), dependency on cardiac inotropes or documented bronchospastic disease
* Any patient on chronic beta blockade as an outpatient.
* Life expectancy \< 48 hours or patients with "do not resuscitate orders"
* Ongoing seizure activity
* Informed consent not obtained
Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with cystic fibrosis.

This single-center pilot study is designed as a double-blind, randomized, cross-over clinical trial to evaluate the effects of inhaled lucinactant, an investigational peptide-containing synthetic surfactant (6 ml of 20 mg total phospholipid (TPL)/mL solution x 5 doses) in patients with mild to moderate CF lung disease. Lucinactant and vehicle will be delivered via a 510k approved vibrating mesh nebulizer, the Pari eFlowTM. The study duration corresponds to a 2-10 day screening phase, followed by a 20 day post-randomization phase that consists of two treatment periods (3 days each) and a washout period (14 days). A total of 16 patients will be enrolled and randomly assigned to one of two treatment sequences (Lucinactant followed by vehicle or vehicle followed by lucinactant). The primary outcome will be the rate of MC, as assessed via gamma scintigraphy, post-lucinactant and post vehicle. Secondary outcomes will include the rate of cough clearance (CC), lung clearance index (LCI), absolute change from baseline in FEV1 after 5 doses of study medication, CF-specific quality of life score (via CFQ-R instrument), in vitro assessments of sputum rheology, and various safety parameters.

Eligibility Criteria:
Inclusion Criteria:

* Cystic fibrosis
* FEV1\>40%

Exclusion Criteria:

* Unstable lung disease
* Unable or unwilling to stop hypertonic saline and dornase alfa for 3 days prior to each study period
* Relevant drug allergy or intolerance
* Recent investigational drug use (30 days)
A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.

The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind, placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be observed after repeated administration of ASC41 in healthy subjects.

Eligibility Criteria:
Inclusion Criteria:

* 1. Age 18-45 (including boundary value). 2. Male weight ≥ 50kg, female weight ≥ 45kg;BMI ranges from 19 to 30kg/m2 (boundary value included).

  3. She is of childbearing potential and is non-pregnant and willing to use adequate contraception from screening (within 30days from the first administration)until one month after the End of Study visit.

  4. The pregnancy test of female subjects during the screening period is negative.

  5. During the screening period, fasting low-density lipoprotein cholesterol (110mg/dl \< fasting (LDL-C) \< 190mg/ dL.

  6. Those who voluntarily sign the informed consent.

Exclusion Criteria:

* 1. Patients with a history of thyroid disease or intolerance to beta blockers or abnormal thyroid function indicators during screening; 2. Previous history of fainting, fainting needle or fainting blood for unknown reasons.

  3. Previous liver disease, or ALT, ASL and direct bilirubin in screening period exceed the normal range.

  4. Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), HIV antibody (HIV Ab) and syphilis antibody are tested positive.

  5. People who have taken special diet (including carambola, dragon fruit, mango, grapefruit, orange, etc.) or drunk alcohol, or had strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion within 2 weeks before taking the study drug.

  6. Heavy smokers (14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine;Smoking daily ≥ 5 sticks) and no smoking or alcohol prohibition during the study period.

  7. Ingesting chocolate, any food or drink containing caffeine or xanthine in the 24 hours prior to taking the study drug.

  8. Patients who had donated blood or lost blood of more than 400ml within 3 months before taking the study drug.

  9. Those who have participated in other clinical trials and received study drug treatment within 3 months before taking study drug.

  10. In addition to the above, the researchers judge that the participants are not suitable to participate in this clinical trial.
Intraoperative Neuromonitoring Recording With a Novel SCS Paddle

The purpose of this study is to demonstrate safety and efficacy of a new spinal cord stimulation paddle electrode which is able to target the dorsal horns, dorsal nerve roots, and dorsal columns. The research electrode ("Study Electrode") is designed to answer basic physiological clinical research questions. It may inform future device therapy development, but the Study Electrode is not a product that will be marketed or sold. The Investigators believe the protocol is a Non-Significant Risk study answering basic physiological research questions, which may be performed under hospital IRB approval.


Eligibility Criteria:
Inclusion Criteria:

* patients undergoing a spinal cord stimulation procedure for neuropathic pain
* must be fluent in English as well as mentally competent to read and answer the questionnaires, as well as complete pain assessment exams.
* subjects must be able to give informed consent.

Exclusion Criteria:

* patients who are not undergoing thoracic spinal cord stimulation for chronic neuropathic pain